1. Cooper N, Rao K, Gilmour K, et al. 2006; Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lympho-histiocytosis. Blood. 107:1233–6. DOI:
10.1182/blood-2005-05-1819. PMID:
16219800.
Article
2. Marsh RA, Jordan MB, Filipovich AH. 2011; Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lympho-histiocytosis: an important step forward. Br J Haematol. 154:556–63. DOI:
10.1111/j.1365-2141.2011.08785.x. PMID:
21707584. PMCID:
PMC3155668.
Article
4. Ouachée-Chardin M, Elie C, de Saint Basile G, et al. 2006; Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 117:e743–50. DOI:
10.1542/peds.2005-1789. PMID:
16549504.
6. Henter JI, Samuelsson-Horne A, Aricò M, et al. 2002; Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immuno-chemotherapy and bone marrow transplantation. Blood. 100:2367–73. DOI:
10.1182/blood-2002-01-0172. PMID:
12239144.
Article
7. Cesaro S, Locatelli F, Lanino E, et al. 2008; Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retro-spective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica. 93:1694–701. DOI:
10.3324/haematol.13142. PMID:
18768529.
Article
8. Baker KS, Filipovich AH, Gross TG, et al. 2008; Unrelated donor hematopoietic cell transplantation for hemophagocytic lympho-histiocytosis. Bone Marrow Transplant. 42:175–80. DOI:
10.1038/bmt.2008.133. PMID:
18454181.
Article
9. Marsh RA, Vaughn G, Kim MO, et al. 2010; Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 116:5824–31. DOI:
10.1182/blood-2010-04-282392. PMID:
20855862.
Article
10. Koh KN, Im HJ, Chung NG, et al. 2015; Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lympho-histiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party. Eur J Haematol. 94:51–9. DOI:
10.1111/ejh.12399. PMID:
24935083. PMCID:
PMC7163615.
Article
11. Cooper N, Rao K, Goulden N, Webb D, Amrolia P, Veys P. 2008; The use of reduced-intensity stem cell transplantation in haemo-phagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant. 42(Suppl 2):S47–50. DOI:
10.1038/bmt.2008.283. PMID:
18978744.
Article
12. Messina C, Zecca M, Fagioli F, et al. 2018; Outcomes of children with hemophagocytic lymphohistiocytosis given allogeneic hematopoietic stem cell transplantation in Italy. Biol Blood Marrow Transplant. 24:1223–31. DOI:
10.1016/j.bbmt.2018.01.022. PMID:
29410181.
Article
15. Henter JI, Horne A, Aricó M, et al. 2007; HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48:124–31. DOI:
10.1002/pbc.21039. PMID:
16937360.
Article
16. Przepiorka D, Weisdorf D, Martin P, et al. 1995; 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15:825–8. PMID:
7581076.
18. Ohga S, Kudo K, Ishii E, et al. 2010; Hematopoietic stem cell trans-plantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 54:299–306. DOI:
10.1002/pbc.22310. PMID:
19827139.
Article
19. Shenoy S, Grossman WJ, DiPersio J, et al. 2005; A novel reduced- intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 35:345–52. DOI:
10.1038/sj.bmt.1704795. PMID:
15592491.
Article
20. Marsh RA, Madden L, Kitchen BJ, et al. 2010; XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 116:1079–82. DOI:
10.1182/blood-2010-01-256099. PMID:
20489057. PMCID:
PMC2938130.
Article
21. Oshrine BR, Olson TS, Bunin N. 2014; Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced- intensity conditioning regimen for non-malignant disease. Pediatr Blood Cancer. 61:1852–9. DOI:
10.1002/pbc.25113. PMID:
24939325.
Article
22. Naik S, Eckstein O, Sasa G, et al. 2020; Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 188:e84–7. DOI:
10.1111/bjh.16370. PMID:
31989587.
Article